At a glance
- Originator Scios
- Class Anti-inflammatories; Antiplatelets; Antirheumatics; Branched-chain amino acids; Small molecules
- Mechanism of Action Immunosuppressants; Platelet aggregation inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Asthma; Myocardial ischaemia; Rheumatic disorders; Thrombosis; Ulcerative colitis
- Discontinued Atherosclerosis; Transplant rejection